Award Number: DAMD17-98-1-8011

TITLE: Novel Mechanisms of Tumor Promoter Activity by Estrogenic Xenobiotics

PRINCIPAL INVESTIGATOR: Robert M. Bigsby, Ph.D.

CONTRACTING ORGANIZATION: Indiana University
Indianapolis, Indiana 46202-5167

REPORT DATE: April 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**4. TITLE AND SUBTITLE**
Novel Mechanisms of Tumor Promoter Activity by Estrogenic Xenobiotics

**6. AUTHOR(S)**
Robert M. Bigsby, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**
Indiana University
Indianapolis, Indiana 46202-5167

E-Mail: rbigsby@iupui.edu

**9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**13. ABSTRACT (Maximum 200 Words)**
Tumor promoter activity of estrogens and xenoestrogens is under investigation. Using the methylxenobiose (MNU) treated rat, estrogens alone could not fully substitute for ovarian factors in mammary tumorigenesis. Estradiol or estrone replacement yielded 25% or 50% tumor incidence in ovariectomized rats. When progesterone was also administered alone it had no tumor promoting effect; treatment with progesterone plus estrone produced a 75% incidence. Thus, there is a synergy between progesterone and estrogen in mammary tumorigenesis.

The xenoestrogen, B-hexachlorcyclohexane (B-HCH) did not significantly promote tumorigenesis. Only 5 of 32 ovariectomized rats treated with B-HCH had tumors 6 months after MNU injection; this was not different from tumor incidence in the control group. Dietary restriction did not affect the rate of tumorigenesis.

Both B-HCH and another pesticide residue, o,p'-DDT induced growth of a human tumor xenograft in athymic mice. However this assay was inconsistent from between experiments and no conclusions could be drawn as to the effect of dietary restriction.

Low blood levels of xenoestrogen were associated with significant increases in estrogenic endpoints in ovariectomized mice. Levels averaging 42 ng/ml or 18 ng/ml for B-HCH or o,p'-DDT, respectively produced increases in vaginal epithelial proliferation and induced hypertrophy of uterine epithelium. These levels are in the same order of magnitude as human blood levels.

**17. SECURITY CLASSIFICATION OF REPORT**
Unclassified

**19. SECURITY CLASSIFICATION OF ABSTRACT**
Unclassified

**15. NUMBER OF PAGES**
23

**18. SECURITY CLASSIFICATION OF THIS PAGE**
Unclassified

**20. LIMITATION OF ABSTRACT**
Unlimited
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature]

Date
# TABLE OF CONTENTS

Front Cover 1
Form 298 2
Foreword 3
Introduction 5

Body of Report

1. MNU-Induced Mammary Tumors in Rats 6
2. Mouse Model – MCF-7 Xenografts & Reproductive Tract Responses 9
3. Ovariectomized Mouse Model – Uterine & Transfection Vaginal Epithelial Bioassays 11
4. Relevance to Statement of Work 13

Conclusions 14
References 16
Table and Figures 18
I. INTRODUCTION

Tumorigenesis is classically divided into two steps, initiation and promotion. Initiation is likely to be the result of some genotoxic insult. Tumor promotion depends on increased growth of the initiated cell and it may be the result of another genotoxic insult to growth regulatory machinery or it may derive from epigenetic stimuli that are normally involved in regulating growth of the original target tissue. Because of its role in mammary gland development, estrogen has long been suspected to behave as a tumor promoter of mammary cancer. This notion is supported by the fact that mammary tumor growth may be inhibited by antiestrogens. It follows that xenoestrogens could supply tumor promoter activity to initiated mammary cells. The studies devised under this grant are designed to examine the tumor promoter activity of two xenoestrogens, o,p'-DDT and β-hexachlorocyclohexane (β-HCH), to define the role of fat stores of these compounds in mammary tumorigenesis, and to determine the molecular mechanism of estrogenic action of o,p'-DDT and β-HCH.

The body of this report will be divided into sections according to research models studied: 1) the rat methylnitrososourea (MNU)-induced mammary tumor model; 2) human mammary tumor xenograft in athymic mice; 3) the ovariectomized mouse uterine and vaginal epithelial bioassays. The Results and Discussion subsection of each report will deal with the scientific significance of the observations made to date, while a separate section will be allotted to the discussion of the relevance to the original Statement of Work.
II. BODY OF REPORT

1. MNU-INDUCED MAMMARY TUMORS IN THE RAT

A. BACKGROUND & INTRODUCTION
MNU induces estrogen-dependent mammary tumors in the rat and this has become a
standard model system for testing tumor growth inhibiting activity of potential
estrogen antagonists. Since injected MNU is fully oxidized and disappears from the
animal's system within a matter of less than one hour (1-3), it must produce its tumor
initiating effects within minutes of administration. Fully mature, young rats (age, 49-56
days) have been shown to respond optimally to the tumorigenic effect of MNU.
Estrogen-dependence of MNU-induced tumors is demonstrable by the following
observations: ovariectomy or antiestrogen treatment performed after MNU initiation
blocks tumor development; ovariectomy leads to tumor stasis or shrinkage and
estrogen replacement will cause resumption of tumor growth. In other model systems
the xenoestrogens, o,p'-DDT and β-HCH have been shown to support growth of
experimental mammary tumors and/or human breast cancer cells in culture (4, 5).
These observations suggest that estrogen is the ovarian factor that is required for
tumor progression and that xenoestrogens can substitute for the natural hormone in
this regard. However, the tumor promoter activity of estrogens has not been tested
directly in the standard MNU rat model.

A study was designed to address the question of whether estrogen behaves as a tumor
promoter in the MNU-initiated rat model. There is only one prior report in which
MNU-treated animals were ovariectomized before detectable tumors were formed and
then treated with estrogen to promote tumorigenesis (6). That study was performed in
an unorthodox protocol in which neonatal (2-day-old) rats were treated with MNU,
followed by tamoxifen treatment until 30 days of age, at which time animals were
ovariectomized, and then estrone treatment was begun at 3.5 months of age. In this
protocol, 50% (6/12) estrogen reconstituted animals developed tumors compared to
rates of 80% (35/44) in ovary-intact control animals and 4% (1/27) in ovariectomized,
untreated, MNU-initiated rats. Thus, from this single study, it would appear that
estrogen can act as tumor promoter in an MNU-initiated mammary gland and
therefore estrogen-replacement in ovariectomized MNU-initiated animals should serve
as the positive control for the xenoestrogen studies.

In our study, animals (49-56 days old) were ovariectomized at the time of MNU
treatment and either supplied with a continuous release estrogen capsule or received no
further treatment. The notion that estrogen serves a tumor promoter in the mammary
gland was directly tested in this manner. In addition, this model was used to test of
whether xenoestrogen treatment of ovariectomized rats would be sufficient to insure
tumor progression. The experiments completed to date tested the tumor promoter
activity of estradiol and estrone, the latter being a weaker estrogen that predominates
in postmenopausal women and which may be more comparable to the weakly
estrogenic xenobiotics. Our earlier data indicated that animals supplemented with
estradiol had a tumor incidence of only 24% while those treated with estrone had a 55%
tumor incidence. Thus, there may be a fundamental difference in the tumor promoter
activity of these two estrogens, and neither alone is sufficient to reproduce the effect of
the ovary. Further experiments were performed in which estrone and progesterone were administered in an attempt to achieve full tumor promoter activity.

Others had reported that high doses of estrogen, with or without progesterone, could actually protect against MNU-induced tumorigenesis (7). It may be that the estrogen treatments applied in our experiments are also exerting a degree of protection, and that the final tumor incidence is a matter of balance between tumor promoter and anti-tumor action of the estrogen. Thus, groups of MNU-treated, ovary-intact animals were treated with estradiol or estrone.

B. METHODS
Sprague-Dawley rats (49-56 days old) were ovariectomized and treated with 50 mg/kg MNU (Sigma Chemical Co., St. Louis, MO) by tail vein injection while still under anesthesia (Ketamine). At the time of ovariectomy, a treatment capsule was implanted subcutaneously in each animal. The capsules were made from Silastic tubing (Konigsberg Instruments, Pasadena, CA, 0.062 in. I.D. X 0.125 in. O.D. X 1.4 cm length), sealed at each end with Silastic cement and containing 26-30 mg of crystalline estrone, or in the case of the negative control group, the implants remained empty. The effect of estrone was further examined by reducing its dose; capsules were made with estrone at a 1:100 dilution by mixing it with crystalline cholesterol. Groups of animals were also treated with progesterone alone or in combination with estrone (at full strength or at 1:100); the progesterone was delivered in a single capsule made as with estrone. As a positive control, animals were left intact and implanted with empty Silastic capsules. In two other groups, animals were left intact, treated with MNU and had a single capsule of estradiol or estrone implanted at the time of MNU treatment. Beginning at 4 weeks after treatment and continuing through 26 weeks, animals were palpated on a weekly basis to determine the time at which tumors appeared in each animal.

The effects of β-HCH were tested in two additional groups of animals. Each of these animals received 4 implants of β-HCH and one group was placed on periodic dietary restriction throughout the 6 month observation period. Dietary restriction consisted of giving animals 40% of their usual daily intake for 1 week out of every three weeks.

At the end of the experiment (26 weeks), animals were killed by cervical dislocation. Whole body, pituitary, and uterine weights were recorded; tumors were collected and processed for histologic examination. Each animal was skinned to allow visualization of the mammary glands to determine if small tumors had escaped detection during palpation. Mammary tumors were dissected out and processed for histologic examination.

Mammary glands were also examined by the whole mount technique as described previously (last annual report). In addition to the experimental animals described above, groups of animals were ovariectomized and treated with hormone as above, without MNU injection. Animals in these treatments were killed at 24 h, 1 week, or 1 month for collection of blood. The mammary glands of animals killed at 1 month were prepared for whole mount observation. Blood serum was sent to Dr. Clinton Grubbs, University of Alabama for analysis of estradiol and progesterone levels.
Tumor incidence was analyzed by Chi-square analysis. All other parameters were analyzed by ANOVA, followed by Fisher’s PLSD to test for differences between individual treatment groups.

C. RESULTS & DISCUSSION
We previously reported that tumor incidences in the ovariectomized animals were 55% (6/11) of estrone-treated and 24% (5/21) of estradiol-treated animals. The ovariectomized, MNU-treated controls produced no tumors, while 100% of the intact, MNU-treated controls had tumors. Furthermore, uterine and pituitary weights indicated that the estrogen treatments remained effective at the end of the 8 month experiment.

Since maximal tumor incidence was reached by 6 months in our earlier experiment, we analyzed this parameter at 6 months in the present set of animals. Estrone produced a 45% incidence and this was increased to 75% in the estrone plus progesterone group (Figure 1). The diluted estrone was ineffective with or without the addition of progesterone.

Examination of mammary glands by whole mount preparation showed that one month of hormone treatment induced a growth response in the tissue (Fig. 2). Mammary glands of intact control animals had an abundance of end buds decorating the ducts, while the ducts of ovariectomized animals were straight and had very few end buds. Treatment with estrone or estradiol induced growth of the mammary tree such that the ducts were decorated with end buds, but not to the extent of the normal gland. Progesterone alone had no effect on mammary gland growth. The combination of progesterone and estrone produced and even greater growth response.

Estradiol and progesterone blood levels during this initial treatment were analyzed as in the previous report. Blood estrogen levels were analyzed using a radioimmunoassay for estradiol; in the manner used, the assay measures both estrone and estradiol. In estrone-treated animals, estrogen levels reached a peak of 60-80 pg/ml during the first week, returning to 40 pg/ml by one month. We had previously reported that the estrogen concentrations were 18-24 pg/ml after 8 months of treatment (previous report).

In intact animals, both estradiol and estrone exerted a protective effect (Fig. 3). In this respect estradiol was the more efficient hormone, reducing the tumor incidence by 67% compared to a 44% reduction from estrone.

Clearly, estrogens produced a tumor promoter effect in this MNU model system. However, in light of the obvious growth response that the estrogen treatments produced, the lack of a full tumor promoter activity seemingly poses a paradox. Earlier studies have shown that large doses of estrogen will protect against tumor formation in MNU-treated rats (7); furthermore, it was recently suggested by Guzman et al (8) that this effect is dependent upon a sufficient dose of estradiol to attain pregnancy levels of hormone in the blood serum (ca. 150 pg/ml) for only one week. It may be that the low incidence of tumors in our estradiol-treated group can be attributed to this protective effect. We had estimated that our Silastic capsules release approximately 1 µg estradiol/day (9). During the first week of treatment blood levels of estrogen were as
high as 80 pg/ml and at the end of 40 weeks, serum estrogen was 25-30 pg/ml in estradiol-treated animals and 18-24 pg/ml in estrone-treated animals. The data reported by Guzman et al (8) not only showed that the highest dose of estradiol used in their experiments was effective at reducing tumor incidence in MNU-treated rats but a dose of one-tenth that which produced the pregnancy levels of estradiol in blood was similarly effective, and a further 10-fold reduction of dose still produced some protective effect. We too found that low estradiol levels can exert protective effects in the MNU-treated rat. Thus, estrogen can have both a protective effect and a promoting effect on mammary gland tumorigenesis. The biphasic nature of the hormone's effect in this regard is not atypical of hormone action in general but it requires further investigation to determine the boundary between these two opposing responses.

β-HCH was ineffective as a tumor promoter, with or without dietary restriction. Only 5 of the 32 animals in the two β-HCH groups (± dietary restriction) had tumors, this was not significantly different from the ovariectomized control group rate of 1 out of 30.

2. MOUSE MODEL – MCF-7 XENOGRAFTS

A. BACKGROUND & INTRODUCTION
The xenograft of human tumor cells in athymic mice has become another standard model for testing the tumor growth promoting or inhibiting effects of a test compound. We had shown earlier that β-HCH stimulated growth of tumors produced from the human breast cancer cell line, MCF-7 (5). In that study, host animals were treated with a single Silastic capsule containing either β-HCH or estradiol; tumor growth was essentially equivalent for both treatments over a 16 day period.

As of our last Annual Report, these observations could not be reproduced. The tumors produced exhibited a much slower growth rate than earlier and they were not at all responsive to xenoestrogen. We have made two additional attempts to repeat that earlier observation.

B. METHODS
MCF-7 Xenograft Experiment
Two separate experiments were performed. In each case host animals (5-6 week old, athymic, female Balb/c mice) were implanted with tumor that was derived from tumors passaged in athymic mice. The original tumor was produced by injection 10^7 MCF-7 cells in Matrigel subcutaneously, as described in the previous report. Once the resultant tumor reached 1.5 cm diameter, the host was killed and the tumor was excised. Tumor tissue was minced and passed through an 40 guage stainless steel mesh (Celllector) and suspended in culture medium (DMEM). The tumor tissue was washed by allowing the fragments to settle out of suspension, removing and replacing the medium. A final suspension was made to 50% (vol/vol) and this was used for injection. Each host animal received two subcutaneous injections (100 µl) of tumor slurry through an 18 guage needle.

In the first experiment, a single Silastic capsule containing estradiol was inserted subcutaneously at the time of tumor implantation. After 5 weeks of tumor growth, the estradiol capsules were removed from 28 animals and 16 of these were treated by inserting 4 capsules of β-HCH into each animal, the other 12 animals were left
untreated. There were 6 animals in which the original E2 capsule remained; these served as positive controls. After one additional week, 8 of the β-HCH-treated animals and 6 of the untreated animals were placed on periodic food restriction; they received 50% of the normal food intake for 3 days of each week. Tumors were measured with calipers and tumor volumes were determined, as described earlier.

In experiment no. 2, the tumor used was derived from a tumor that grew slowly in an intact athymic host without added E2. It was hoped that this tumor would prove more sensitive to weak estrogens. This tumor was transplanted to experimental host animals and each host was given three daily injections of estradiol (10 μg/kg/day) to insure tumor take and initial growth. Three weeks after the last E2 injection, groups of animals received a single capsule of E2, 4 capsules of o,p'-DDT, or 4 capsules of β-HCH and tumor growth was followed on a weekly basis; animals that received no further treatment after the initial injections served as negative controls. Tumor volume was measured on a weekly basis.

C. RESULTS AND DISCUSSION
As of our last Annual Report, the original observations of xenoestrogen-induced tumor growth could not be reproduced. The tumors produced exhibited a much slower growth rate than earlier and they were not at all responsive to xenoestrogen. Further attempts to repeat this original observation have produced mixed results. Figures 4 and 5 show the growth responses in two separate experiments. In the first experiment, tumor was initially stimulated by implantation of an estradiol capsule. Experimental treatments began with removal of the E2 capsule after 5 weeks of growth; at this time the average tumor volume was equal to 570 mm³. In this experiment, β-HCH did not substitute for E2 (Fig. 4); furthermore, fasting had no effect on tumor growth.

In the second experiment the implanted tumor tissue came from a tumor that had grown in an intact female host without steroid supplementation. In this case the tumor volume at the beginning of the experimental treatments was much smaller, with an average of 45 mm³. These tumors grew under estradiol and o,p'-DDT stimulation; β-HCH produced only a small growth effect (Fig. 5). This is in contrast to the original experiments which indicated that β-HCH was as active as estradiol in this growth assay (5).

The reasons for the inconsistencies in this tumor growth assay are unknown. Perhaps there has been a subtle change in the character of the MCF-7 cells used. Unfortunately, due to an accident in the lab we have lost all of the early passages of the MCF-7 cell stock. Clearly, the original tumors grew at a much faster rate and they continued growth for several days without estradiol supplementation (5). Also, the size of the tumor at the initiation of experimental treatment may be very important; here, the very small tumors responded to o,p'-DDT and β-HCH while the tumors that were large at the outset did not respond.
3. OVARIECTOMIZED MOUSE MODEL – UTERINE & VAGINAL EPITHELIAL BIOASSAYS

A. BACKGROUND & INTRODUCTION
As indicated in the last Annual Report, blood and tissue levels attained following implantation of Silastic capsules containing either β-HCH or o,p′-DDT were related to the biological response in ovariectomized mice. In our earlier report it was shown that all doses used produced significant estrogenic effects. Thus, the treatment regime needed to be extended to lower doses to establish the lowest blood levels which would be associated with a significant increase in estrogenic endpoints. This study is completed and has yielded surprising dose-response information.

B. METHODS
Dose-Response of o,p′-DDT and β-HCH administered to mice.
Animal treatment: Silastic capsules were made as described above with the exception that the length of capsule containing crystalline compound was 0.8 cm so that each capsule contained 18-22 mg of material. To achieve lower doses, the crystalline test compound, o,p′-DDT or β-HCH, were diluted by mixing with crystalline cholesterol. Mixtures were made to yield 1/2, 1/4, or 1/8 of the dose. Adult ICR mice were ovariectomized and 3 weeks later groups of five animals received 1 treatment capsule containing either undiluted or diluted test compound, some animals received 2 capsules at 1/2 dilution, and others received 2, or 4 capsules of undiluted treatment compound. Thus, this regimen covered a 32-fold range of doses. A positive control group consisted of animals that received a Silastic capsule containing estrone (Sigma) and negative control animals were treated with an empty Silastic capsule. After 1 week of treatment, animals were anesthetized and exsanguinated by heart puncture. The uterus and vagina of each animal was processed for histomorphometric determination of the estrogenic effects; blood serum and intraperitoneal fat samples were analyzed for o,p′-DDT or β-HCH content by gas chromatography.

Histomorphometrics and Blood Levels of o,p′-DDT or β-HCH: As described in the previous report, the height of the uterine epithelium and thickness of the vaginal epithelium were used as endpoints of estrogenic activity. These parameters were then correlated to blood levels of o,p′-DDT or β-HCH as measured by gas chromatography (see methods in previous report).

C. RESULTS AND DISCUSSION
Blood and fat levels of β-HCH or o,p′-DDT correlated linearly (Fig. 6). It is apparent from these linear increases that saturation of the tissues has not been reached, even at the highest dose applied. Macholz et al (10) showed that feeding rats food containing either 600 or 3000 ppm β-HCH produced concentrations in the fat of 250 µg/g or 210 µg/g, respectively, at 30 days, indicating that the fat was saturated. The highest level achieved in our study was 55 µg β-HCH/g fat tissue at the end of one week of treatment. In an earlier study, Dale et al (11) reported that feeding rats 200 ppm of DDT for 90 days produced fat levels of 729-2206 µg/g in female rats. In our study, after one week with 4 treatment capsules the fat levels of op-DDT were 56-99 µg/g.

The lowest dose of compound used in this mouse study produced blood and fat levels that were similar to levels recorded in humans with no history of excess exposure. The
lowest dose of o,p'-DDT in our study produce blood levels of 4.4 ± 0.61 ng/ml and fat levels of 265 ± 19 ng/g. Human blood levels of all isomers of DDT and their metabolites are generally 5-30 ng/ml (12). Although the o,p'-isomer is only a very small proportion of total DDT isomers contaminating the environment, a group of Israeli men were found to have blood levels of o,p'-DDT as high as 32 ng/ml (12). In the present mouse study, the lowest dose of β-HCH produced blood levels of 5.0 ± 0.97 ng/ml. Human blood levels of β-HCH are generally 0-5 ng/ml but have averaged as high as 23 ng/ml in non-exposed populations or as high as 240 ± 140 ng/ml in occupationally exposed populations (12).

Uterine epithelium exhibits both hypertrophic and hyperplastic responses to estrogen stimulation. The hyperplastic response is apparent from the extremely crowded character of the epithelium; although it is a simple type of epithelium, under estrogen stimulation it takes on the appearance of a stratified layer of cells, i.e. it becomes pseudostratified. The hypertrophic response of the epithelial cell is apparent from its increase in cell height. Upon ovariectomy, the columnar epithelium becomes cuboidal with an average height of approximately 7.7 μm; stimulation with estrone increased the epithelial height to 25 μm (Table 1). o,p'-DDT increased uterine epithelial height to 26 μm in a dose dependent fashion. The uterine response to β-HCH was quite different; a single treatment capsule produced a significant increase in epithelial cell height, to 12 μm, but there was no further increase with increasing dose.

Vaginal epithelium undergoes a dramatic increase in cell proliferation in response to estrogenic stimulation. With full stimulation from a strong estrogen the superficial layer of cells loose their nuclei and organelles to become a flattened layer of keratin; continuous stimulation produces multiple laminations within this keratinized superficial layer. In the ovariectomized control animals the epithelium consisted of a very low layer of squamous cells that was one to two cells thick, approximately 12 μm. Estrone-treated animals had a vaginal epithelium that was multilayered with a fully keratinized surface layer; the epithelial thickness, below the keratinized layer, was 78-97 μm. Thickness of the vaginal epithelium was increased in a dose-dependent manner after treatment with either o,p'-DDT or β-HCH (Table 1). The epithelium was keratinized in animals treated with the 3 highest doses of o,p'-DDT. In β-HCH-treated animals, only two of the five animals with four treatment capsules exhibited a keratinized epithelium and none of the others had a keratinized surface layer. Thus there appears to be both a quantitative and a qualitative difference between the estrogenic characters of β-HCH and o,p'-DDT.

The object of these dose-response studies was to determine the lowest dose of compound that would produce an estrogenic effect and to correlate tissue levels against the estrogenic effect. This would aid in completion of our present studies in that knowing the effective blood and tissue levels will help in the interpretation of the data on tumor growth in both the rat model (above) or in the mouse xenograft model. It would also be useful for comparing known human blood and tissue levels against putative estrogenic effects. We found that blood levels of 18 ± 2.3 ng/ml o,p'-DDT or 42 ± 3.6 ng/ml β-HCH were associated with statistically significant increases in estrogenic endpoints. Thus, blood levels that are within the same order of magnitude as those found in humans have proved to be estrogenic.
4. RELEVANCE TO STATEMENT OF WORK

YEAR 2, ORIGINAL SOW

Aim 1: Complete experiment on tumor promoter effects under continuous treatment; process tissues (breast tumors, uteri, vaginas); analyze data. Begin tumor promoter experiment with animals that are fed or diet-restricted. Collect and analyze blood and tissue samples from this experiment.

Aim 2: Complete xenograft experiments with fed vs. fasted hosts. Collect and analyze blood samples.

Aim 3: Begin and complete transfection experiments.

PROGRESS TO DATE:

Aim 1: Most of the work to date on this, the main aim of the project, has centered around a determination of the effectiveness of natural estrogens to promote mammary tumorigenesis. It was found that estradiol or estrone alone promote tumors only partially, i.e. they produce tumor incidences of about 25% and 50%, respectively, in ovariectomized animals. When progesterone was added, estrone induced tumors in 75% of the animals; progesterone alone had no effect. Thus, there is a synergistic tumor promoter activity of progesterone and estrone and this synergy is required for full tumorigenic activity.

A single experiment has been performed in which the xenoestrogen, \( \beta \)-HCH, was administered to ovariectomized, MNU-treated animals. In addition, this experiment included a group of \( \beta \)-HCH-treated animals that were placed on periodic food restriction. There was no indication that \( \beta \)-HCH acted as a tumor promoter on its own. Further work is required to determine if progesterone plus xenoestrogen will promote tumorigenesis.

Aim 2: After 3 experiments, this tumor growth assay has behaved inconsistently. The rate of tumor growth in all 3 experiments did not approach that of our original, published observations. \( \beta \)-HCH was only slightly stimulatory in one of the three experiments and o,p'-DDT was fully stimulatory in one of two experiments in which it was tested. The only experiment in which fasting was added as a variable, the xenoestrogen under test, \( \beta \)-HCH was ineffective, with or without food restriction. Thus, there are no solid conclusions to be drawn from these experiments.

Aim 3: Work on this aim was completed.
III. CONCLUSIONS

Although the standard MNU-initiated rat model would seem to be the ideal model system for doing so, the tumor promoter effects of ovarian hormones has never been established in this system. Our studies have shown that stimulation of mammary gland growth by estradiol or estrone is not in itself sufficient to promote tumorigenesis to same extent as the intact ovary. In addition, it appears that there is a biphasic response to estrogens: they are able to both inhibit and promote tumorigenesis. Although it was considered controversial (13), it may be that progesterone supplied by the ovary is also essential for full tumor promoter activity. This was tested in the ovariectomized rat. Progesterone alone had no promoter effect but it synergistically enhanced estrone's tumor promoter activity. This supports the recent epidemiological findings that combined hormone replacement therapy, estrogen plus progestin, is associated with an increased risk for breast cancer (14, 15).

The studies on estrogenic effects of op-DDT and β-HCH in the mouse reproductive tract have produced some startling results. This is the first study in which blood levels of test compound were correlated to estrogenic response. In past reports xenoestrogens were administered in very large doses (100-500 mg/kg BW) and acute estrogen responses were monitored (4, 16-19). The impression from such studies was that xenoestrogens, being very weakly estrogenic by a number of in vitro assays (19-22), required the very large doses of compound to have an effect in vivo. In our study the compounds were delivered continuously in low doses. The blood levels attained by the highest doses in the mice were well above those which are found in the general population of people. However, the lowest dose that induced significant biological effects in the mice produced blood levels that were within the same order of magnitude of blood levels found in some non-exposed humans (12). Thus, under the condition of a continuous low level of exposure, estrogenic effects can be expected from levels of xenoestrogen commonly encountered in humans.

The MCF-7 xenograft studies have been inconsistent and no conclusions can be drawn at this date. The tumors formed from the cells now available do not seem to have the same growth characteristics as those of our earlier study. And xenoestrogens have inconsistently stimulated tumor growth. In the single experiment in which food restriction was applied, the xenoestrogen was ineffective with or without dietary restriction.

The year 1 studies on the estrogen receptor domains which participate in estrogen and xenoestrogen transcriptional activation have given us some clues as to how compounds can produce qualitatively and quantitatively disparate effects in the same tissue. Compounds such as BPA, octylphenol, and β-HCH are fully effective compared to estradiol when the wild-type receptor is present; o,p'-DDT produces a super-activation of the reporter gene. Deletion of either AF-1 or AF-2 results in a loss of relative efficacy of the xenoestrogens. Thus, they appear to require a synergy between the two activation function domains. Recent observations by Nishikawa (23) suggest that the different compounds are likely to produce different receptor–coactivator interactions. The fact that o,p'-DDT consistently produced a greater response than estradiol suggests that it may enhance binding of coactivator to receptor. Such differences in molecular
activity of compounds should be considered when attempting to assess their potential bioactivity.
V. REFERENCES


Table 1. Blood Concentrations and Biological Endpoints. Mean values of blood serum concentrations, uterine epithelial cell height (UEH) and vaginal epithelial thickness (VET) were determined for each treatment/dosage group. For o,p'-DDT and β-HCH, dosage groups are listed as A-G for treatments with a single diluted capsule (1/8, 1/4, 1/2), a single undiluted capsule (1) or multiple capsules (2X 1/2, 2, 4). Values are presented as means ± SEM; numbers in parentheses following the mean refer to the number of samples analyzed. *, p < 0.05 or **, p < 0.005 compared to control; nd, not determined

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Blood Conc. (ng/mL)</th>
<th>UEH (µm)</th>
<th>VET (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
<td>7.74 ± 0.32 (5)</td>
<td>11.7 ± 0.94 (5)</td>
</tr>
<tr>
<td>Estrone</td>
<td>nd</td>
<td>25.5 ± 3.5 (5)**</td>
<td>79.6 ± 6.6 (5)**</td>
</tr>
<tr>
<td>o,p'-DDT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (1/8)</td>
<td>4.4 ± 0.61 (4)</td>
<td>7.88 ± 0.62 (4)</td>
<td>14.3 ± 2.5 (4)</td>
</tr>
<tr>
<td>B (1/4)</td>
<td>5.2 ± 0.91 (3)</td>
<td>8.93 ± 0.22 (3)</td>
<td>14.7 ± 0.87 (3)</td>
</tr>
<tr>
<td>C (1/2)</td>
<td>23 ± 13 (2)</td>
<td>9.15 ± 0.66 (3)</td>
<td>20.0 ± 1.7 (4)*</td>
</tr>
<tr>
<td>D (2X1/2)</td>
<td>18 ± 2.3 (3)</td>
<td>12.0 ± 0.95 (5)**</td>
<td>39.7 ± 7.0 (5)**</td>
</tr>
<tr>
<td>E (1)</td>
<td>190 ± 40 (4)</td>
<td>11.4 ± 1.6 (4)*</td>
<td>63.9 ± 10 (4)**</td>
</tr>
<tr>
<td>F (2)</td>
<td>260 ± 26 (4)</td>
<td>15.7 ± 1.9 (4)**</td>
<td>85.3 ± 21 (4)**</td>
</tr>
<tr>
<td>G (4)</td>
<td>620 ± 150 (4)</td>
<td>26.0 ± 1.7 (4)**</td>
<td>114 ± 8.4 (4)**</td>
</tr>
<tr>
<td>β-HCH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (1/8)</td>
<td>5.0 ± 0.97 (3)</td>
<td>8.40 ± 0.61 (4)</td>
<td>12.1 ± 1.7 (4)</td>
</tr>
<tr>
<td>B (1/4)</td>
<td>12 ± 3.4 (3)</td>
<td>7.18 ± 0.75 (4)</td>
<td>15.1 ± 1.1 (4)</td>
</tr>
<tr>
<td>C (1/2)</td>
<td>22 ± 2.5 (3)</td>
<td>9.03 ± 1.2 (5)</td>
<td>17.6 ± 4.2 (5)</td>
</tr>
<tr>
<td>D (2X1/2)</td>
<td>42 ± 3.6 (3)</td>
<td>9.97 ± 1.0 (4)</td>
<td>21.9 ± 2.7 (5)**</td>
</tr>
<tr>
<td>E (1)</td>
<td>66 ± 3.9 (3)</td>
<td>12.1 ± 0.61 (4)**</td>
<td>38.3 ± 6.1 (4)**</td>
</tr>
<tr>
<td>F (2)</td>
<td>170 ± 29 (4)</td>
<td>10.8 ± 0.71 (5)*</td>
<td>38.9 ± 2.9 (5)**</td>
</tr>
<tr>
<td>G (4)</td>
<td>300 ± 49 (4)</td>
<td>11.3 ± 0.82 (5)*</td>
<td>58.1 ± 5.2 (5)**</td>
</tr>
</tbody>
</table>
Figure 1. Tumor Incidence in MNU-Treated, Ovariectomized Rats. Rats were ovariectomized, injected with MNU and a Silastic treatment capsule was inserted subcutaneously. Treatment capsules contained crystalline estrone (E1), crystalline estrone at a 1/100 dilution (E1 1/100), or progesterone P4; in one group two capsules containing progesterone or estrone were inserted (P4+E1). Controls included ovary intact animals (intact) and ovariectomized animals (ovxd). The tumor incidence was recorded at 6 months and analyzed by Chi-square. a, p < 0.05 vs ovxd; b, p < 0.05 vs. intact.
Figure 2. Mammary Whole Mounts. Ovariectomized rats were treated for 1 month with an empty Silastic capsule (ovxd), an estrone capsule (E1), or a progesterone capsule and an estrone capsule (P4 + E1). Whole mount preparations were viewed at low (left) and high (right) power on a dissecting microscope.
Figure 3. Tumor Incidence in MNU-Treated, Ovary-Intact Rats. Rats were injected with MNU and a Silastic capsule containing either estradiol (E2) or estrone (E1) was inserted subcutaneously. Ovary intact or ovariectomized (ovxd) rats served as controls for comparisons. a, p < 0.05 vs. ovxd; b, p < 0.05 vs. intact.
Figure 4. Effect of β-HCH on MCF-7 Tumor Growth in Athymic Mice on Dietary Restriction. MCF-7 tumor was transplanted to mice that were under estrogen stimulation via a subcutaneous capsule of estradiol. After 3 weeks the estradiol capsule was replaced with an empty control capsule (cont) or one containing β-HCH (β-HCH). Half of these hosts were placed on periodic dietary restriction (fast) while the others were left on food ad libitum (fed).
Figure 5. Effect of o,p'-DDT or β-HCH on MCF-7 Tumor Growth. Tumor was transplanted from a host that had not been treated with estrogen to maintain the tumor's growth. This tumor was grown for 5 weeks in ovary intact animals with only 3 daily injections of estradiol administered at the time of transplantation.